Staphylococcus aureus is one of the most common causes of hospital-acquired infections. At the same time, 25% of healthy persons are symptom-free S. aureus carriers, and they have an increased risk of developing nosocomial S. aureus septicemia. Paradoxically, their prognosis is much better than that of noncarriers. We compared the antibody profiles for carriers and noncarriers toward S. aureus superantigens. In carriers, we found high titers of neutralizing antibodies specific for those superantigens that are expressed by their colonizing strain. The results show that carriage status confers strainspecific humoral immunity, which may contribute to protection during S. aureus septicemia.
developing severe nosocomial S. aureus infection and sepsis that is, in ∼80% of cases, caused by the colonizing strain [2, 3] . However, compared with noncarriers who have newly acquired S. aureus infections, carriers with S. aureus septicemia seem to have a much better outcome. In a prospective trial, Wertheim et al. [3] found mortality due to S. aureus bacteremia to be much lower in carriers than in noncarriers (3/40 vs. 13/41; odds ratio, 0.1;
). This indicates that the immune system of S. P p .013 aureus carriers may react to S. aureus infections differently than that of noncarriers, which could be due a tuning of the immune response by the colonizing S. aureus strain [4] .
Superantigens (SAgs) can be used to test this hypothesis. First, these secretion products of S. aureus are very potent proinflammatory agents, and they have been implicated in the pathogenesis of septic shock [5] . SAgs cross-link major histocompatibility complex class II molecules on antigen-presenting cells with T cell receptors (TCRs) that use certain TCRVb elements [6] . This leads to very strong T cell proliferation and cytokine secretion, which can result in shock. Moreover, SAgs may induce the upregulation of Toll-like receptor-4 on monocytes and thereby exacerbate their proinflammatory response to endotoxin [7] .
Second, the SAg pattern of different S. aureus strains varies considerably. To date, 19 SAgs have been described: staphylococcal enterotoxins (SE) A-E , G-R, and SEU, as well as toxic shock syndrome toxin (TSST)-1 [6] . Approximately 80% of S. aureus strains harbor multiple SAg genes on mobile genetic elements, which results in highly heterogeneous SAg expression in clinical isolates [6, 8] .
Anti-SAg antibodies are highly prevalent in the healthy population, and it has been shown that humans with high anti-TSST-1 antibody titers do not develop toxic shock syndrome when they become infected with a TSST-1-expressing S. aureus strain [9] . As a consequence, vaccination strategies have been explored in mice using recombinant SAg toxoids or conserved SAg peptides as antigens [10] [11] [12] . The elicited antibody responses conferred protection against toxic shock induced by SAgs, as well as against S. aureus sepsis. Some cross-reactivity with heterologous SAgs and some cross-protection has been observed [10, 12] . In contrast to these approaches, we used SAgs in the present study as strain-specific indicator antigens to address the question of whether there are differences in the antibody response between S. aureus carriers and noncarriers.
Materials and methods. Over the course of at least 3 months, 2 nose swabs and serum samples were obtained from 123 healthy blood donors. All participants gave informed consent, and the study was approved by the ethics board of the University of Greifswald. S. aureus was identified by morphologic identification of colonies on blood agar plates and a S. aureus-specific latex agglutination test (Murex Staphaurex test; Murex Biotech). The SAg gene repertoire of the S. aureus isolates was determined by polymerase chain reaction, as described elsewhere [8] .
Proliferation assays were performed as described elsewhere [8] . Briefly, peripheral blood mononuclear cells (PBMCs) from healthy blood donors were cultured in 96-well flat-bottom plates at a density of cells/well in the presence of RPMI 1640 5 1 ϫ 10 supplemented with 10% fetal bovine serum. The cells were stimulated for proliferation by incubation with S. aureus supernatants (OD, 3.0) in serial dilutions or by individual SAgs, which were produced by recombinant gene technology (SEA, TSST-1, and SEC3) [13] or purified from bacterial cultures (SEB; Sigma). To test for SAg neutralizing serum factors, heat-inactivated human serum was added at a final concentration of 2%. Proliferation was determined by the incorporation of [ Results and discussion. Of 123 healthy blood donors 22 (18%) were twice positive for S. aureus (constant carriers), whereas 70 (57%) were twice negative (noncarriers). This is consistent with the results of previous studies [1] . The SAg gene repertoire of the colonizing strains was very heterogeneous (table  1) . Except for 3 subjects in whom a strain shift occurred, the SAg patterns of the 2 isolates were identical, indicating a clonal relationship, which for 5 samples was confirmed by pulsed-field gel electrophoresis (data not shown).
The prevalence of neutralizing antibodies against the complex SAg mixtures, which are found in S. aureus supernatants, was analyzed in proliferation assays. We excluded the S. aureus isolates harboring no SAg genes, the 3 subjects in whom a strain shift occurred (T9, T166, and T169), and those who only had SAgs encoded by the enterotoxin gene cluster (egc), given that we have recently shown that egc SAgs only very rarely induce neutralizing antibodies [8] . Culture supernatants from the remaining 14 isolates were used to stimulate proliferation in human PBMCs. Taking the AUC as a measurement for inhibition, we compared for each S. aureus strain the neutralizing capacity of the serum obtained from (1) its carrier, (2) a randomly chosen noncarrier, and (3) a carrier whose colonizing strain harbored a nonoverlapping spectrum of SAg genes (figure 1A); 13 (93%) of 14 carriers showed a very effective antibody response that almost abolished T cell proliferation induced by the SAgs of their colonizing strain (figure 1B). In contrast, when secretion products of S. aureus strains expressing different SAgs were assessed, the serum neutralizing capacity of S. aureus carriers was much lower and did not differ from that of noncarriers ( figure 1A and 1B) . Only approximately one-third of the carriers and noncarriers efficiently neutralized the biological effects of SAgs secreted by unrelated S. aureus strains (figure 1B). This likely reflects the individuals' history of immune encounters with different S. aureus strains.
When single recombinant or purified SAgs (SEA, SEB, SEC3, , and purified SEB (circles). We analyzed the neutralizing capacity of the same noncarrier serum and all carrier serum samples (as indicated in table 1), except for those in which a strain shift occurred. Again, all carriers showed a very effective antibody response against those SAgs, which are expressed by their colonizing strain (SAg + carrier). Individual SAgs were neutralized by serum from unrelated carriers (SAg Ϫ carrier) and from noncarriers at a higher frequency than the complex SAg mixtures. NS, not significant and TSST-1) were tested, serum samples from all carriers very efficiently neutralized those SAgs that were present in their colonizing strain ( figure 1C ). Unrelated individual SAgs were generally neutralized more frequently than were the complex SAg mixtures (76%-79%, with 25% proliferation used as a threshold), which are produced by S. aureus wild-type strains ( figure 1C) . Neutralization of the biological SAg effects correlated with antibody binding to purified SAgs as confirmed by ELISA (TSST-1 and SEB; data not shown). These results are in agreement with those of previous studies, which detected SAg-binding antibodies in 40%-95% of serum samples from healthy donors or patients, irrespective of their carrier status [14] [15] [16] .
In contrast to our approach, previous studies have mainly focused on the protection conferred by cross-reactive antibodies, which can be induced by vaccination with SAgs or defined conserved SAg peptides [10] [11] [12] . In agreement with our data, the antibody titers specific for heterologous SAgs were ∼10-fold lower than those directed against the SAgs used for im-munization [10] . These differences were strongly correlated with the degree of protection [10] .
Our results clearly show that the human immune system reacts specifically against the colonizing S. aureus strain, leading to almost complete neutralization of the T cell stimulating effects of its SAgs. Thus, during colonization, conserved epitopes do not appear to be immunodominant. Because, in rodents, 10-fold differences in SAg neutralizing capacity were critical for the outcome of a SAg challenge, our observations could be clinically highly relevant. The specific and effective antibody response in carriers may, in part, explain the paradox observed in a prospective trial. Although S. aureus carriers are at higher risk of acquiring S. aureus septicemia, in the case of sepsis, their outcome is much better [3] . However, one has to bear in mind that S. aureus harbors many more virulence factors besides SAgs. Like SAgs, most of these are encoded on mobile genetic elements, and they are highly variable in clinical isolates. Although we have shown an antibody response against the SAgs of their colonizing strain in S. aureus carriers that may provide some strain-specific protection, further studies are needed to assess their immune response toward other virulence factors.
